Exhibit 99.1

Hepion Pharmaceutical

Consolidated Balance Sheets

January 31, 2025

PBC

		January 31, 2025
		(Unaudited)
ASSETS
Current Assets
Cash		5,219,944.00
Prepaid expenses		1,142,329.00
Related party receivable		-
Total Current Assets	$	6,362,273.00
Property and equipment, net		-
Right-of-use assets		-
Other assets		-
In Process R&D		-
TOTAL ASSETS	$	6,362,273.00
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities		-
Accounts payable		220,202.00
Accrued expenses		23,684.00
Operating lease liabilities, current		-
Notes payable, current		-
Short-term portion of contingent consideration		-
Total Current Liabilities	$	243,886.00
Contingent liability, non-current		-
Operating lease liabilities, non-current		-
Derivative financial instruments-warrants		6,142,303.00
TOTAL LIABILITIES	$	6,386,189.00
Stockholders’ Equity
Series A convertible preferred stock		855,808.00
Series C convertible preferred stock		839,320.00
Common stock		663.00
Additional paid-in capital		236,462,218.00
Accumulated other comprehensive loss		8,345.00
Accumulated deficit		(238,190,270.00	)
TOTAL STOCKHOLDERS’ EQUITY	$	(23,916.00	)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	6,362,273.00